| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.6 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.032 | 0.6 |